|
Cohort1: Ocrelizumab patients after 2nd vaccine
|
| Administration route |
None |
| Pts |
33 |
| Age |
Adult, Older_Adult |
| Outcome |
percentage of MS patients on immunotherapy with a positive SARS-CoV-2 Spike antibody response: 8/33 (24.2%) |
| References |
PMID:
37057191
|
|
|
Cohort2: Ocrelizumab patients after 3rd vaccination
|
| Administration route |
None |
| Pts |
22 |
| Age |
Adult, Older_Adult |
| Outcome |
percentage of MS patients on immunotherapy with a positive SARS-CoV-2 Spike antibody response: 9/22(40.9%) |
| References |
PMID:
37057191
|
|
|
Cohort3: Fingolimod patients after 2nd vaccin
|
| Administration route |
None |
| Pts |
7 |
| Age |
Adult, Older_Adult |
| Outcome |
percentage of MS patients on immunotherapy with a positive SARS-CoV-2 Spike antibody response: 5/7 (71.4%) |
| References |
PMID:
37057191
|
|
|
Cohort4: Fingolimod patients after 3rd vaccine
|
| Administration route |
None |
| Pts |
21 |
| Age |
Adult, Older_Adult |
| Outcome |
percentage of MS patients on immunotherapy with a positive SARS-CoV-2 Spike antibody response: 19/21 (90.5%) |
| References |
PMID:
37057191
|
|
|
Cohort5: Healthy controls after 2nd vaccine
|
| Administration route |
None |
| Pts |
29 |
| Age |
Adult, Older_Adult |
| Outcome |
percentage of MS patients on immunotherapy with a positive SARS-CoV-2 Spike antibody response: 29/29 (100%) |
| References |
PMID:
37057191
|
|
|
Cohort6: Healthy controls after 3rd vaccine
|
| Administration route |
None |
| Pts |
7 |
| Age |
Adult, Older_Adult |
| Outcome |
percentage of MS patients on immunotherapy with a positive SARS-CoV-2 Spike antibody response: 7/7 (100%) |
| References |
PMID:
37057191
|
|